Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The daily Top 10 COVID papers

Breast Cancer

Free Subscription 11.01.2021 1 Am J Pathol 4 Am J Surg 6 Ann Oncol 10 Ann Surg Oncol 3 Anticancer Res 3 BMC Cancer 1 Br J Cancer 9 Breast Cancer 3 Breast Cancer (Auckl) 5 Breast Cancer Res 46 Breast Cancer Res Treat 2 Breast J 1 Cancer 1 Cancer Chemother Pharmacol 4 Cancer Res 2 Clin Breast Cancer 2 Clin Cancer Res 1 Clin Exp Metastasis 4 Eur J Cancer 1 Eur Radiol 1 Histopathology 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 1 J Clin Invest 1 J Clin Oncol 5 NPJ Breast Cancer 3 Oncogene 5 Oncol Rep 1 PLoS Med 2 PLoS One 1 Proc Natl Acad Sci U S A 1 Radiother Oncol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Pathol

1. PARRILLA CASTELLAR ER, Plichta JK, Davis R, Gonzalez-Hunt C, et al
   Somatic Mutations in LRRK2 Identify a Subset of Invasive Mammary Carcinomas Associated with High Mutation Burden.
   Am J Pathol. 2020;190:2478-2482.
   PubMed         Abstract available
   
   

   
   Am J Surg

2. CULLOM ME, Amin AL, Balanoff CR, Wagner JL, et al
   Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant chemotherapy.
   Am J Surg. 2020;220:1225-1229.
   PubMed         Abstract available
   
   
3. LAGENDIJK M, Desantis S, Nakhlis F, Duggan M, et al
   Impact of surgical complications on patient reported outcomes (PROs) following nipple sparing mastectomy.
   Am J Surg. 2020;220:1230-1234.
   PubMed         Abstract available
   
   
4. LAYEEQUR RAHMAN R, Puckett Y, Habrawi Z, Crawford S, et al
   A decade of intraoperative ultrasound guided breast conservation for margin negative resection - Radioactive, and magnetic, and Infrared Oh My....
   Am J Surg. 2020;220:1410-1416.
   PubMed         Abstract available
   
   
5. HAMMOND JB, Han GR, Cronin PA, Kosiorek HE, et al
   Exploring the Effect of Post-mastectomy complications on 5-year survival.
   Am J Surg. 2020;220:1422-1427.
   PubMed         Abstract available
   
   

   
   Ann Oncol

6. YVER A, Agatsuma T, Soria JC
   The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
   Ann Oncol. 2020;31:430-434.
   PubMed        
   
   
7. DENKERT C, Untch M, Benz S, Schneeweiss A, et al
   Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
   Ann Oncol. 2021 Jan 5. pii: S0923-7534(20)43224.
   PubMed         Abstract available
   
   
8. AMIRI-KORDESTANI L, Xie D, Tolaney SM, Bloomquist E, et al
   A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
   Ann Oncol. 2020;31:1704-1708.
   PubMed         Abstract available
   
   
9. KARN T, Denkert C, Weber KE, Holtrich U, et al
   Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
   Ann Oncol. 2020;31:1216-1222.
   PubMed         Abstract available
   
   
10. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    PubMed         Abstract available
    
    
11. KURZROCK R, Bowles DW, Kang H, Meric-Bernstam F, et al
    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Ann Oncol. 2020;31:412-421.
    PubMed         Abstract available
    
    

    
    Ann Surg Oncol

12. KANTOR O, King TA
    ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer.
    Ann Surg Oncol. 2021 Jan 2. pii: 10.1245/s10434-020-09435.
    PubMed        
    
    
13. TADROS AB, Sevilimedu V, Giri DD, Zabor EC, et al
    Survival Outcomes for Metaplastic Breast Cancer Differ by Histologic Subtype.
    Ann Surg Oncol. 2021 Jan 2. pii: 10.1245/s10434-020-09430.
    PubMed         Abstract available
    
    
14. ALLWEIS TM, Hermann N
    ASO Author Reflections: Will Breast Cancer Screening Become Personalized?
    Ann Surg Oncol. 2021 Jan 3. pii: 10.1245/s10434-020-09457.
    PubMed        
    
    
15. PARDO JA, Fan B, Mele A, Serres S, et al
    The Role of Oncotype DX((R)) Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer.
    Ann Surg Oncol. 2021 Jan 3. pii: 10.1245/s10434-020-09382.
    PubMed         Abstract available
    
    
16. ALLWEIS TM, Hermann N, Berenstein-Molho R, Guindy M, et al
    Personalized Screening for Breast Cancer: Rationale, Present Practices, and Future Directions.
    Ann Surg Oncol. 2021 Jan 4. pii: 10.1245/s10434-020-09426.
    PubMed         Abstract available
    
    
17. TADROS AB, Plitas G
    ASO Author Reflections: Clinical Importance of Histologic Subtype for Metaplastic Breast Cancer.
    Ann Surg Oncol. 2021 Jan 5. pii: 10.1245/s10434-020-09454.
    PubMed        
    
    
18. PARTAIN N, Postlewait LM, Teshome M, Rosso K, et al
    The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer.
    Ann Surg Oncol. 2021 Jan 5. pii: 10.1245/s10434-020-09392.
    PubMed         Abstract available
    
    
19. POSTLEWAIT LM, Lucci A
    ASO Author Reflections: The Multidisciplinary Approach to de Novo Metastatic Inflammatory Breast Cancer: A Combined Systemic and Locoregional Strategy.
    Ann Surg Oncol. 2021 Jan 6. pii: 10.1245/s10434-020-09421.
    PubMed        
    
    
20. SIMONS JM, Scoggins ME, Kuerer HM, Krishnamurthy S, et al
    Prospective Registry Trial Assessing the Use of Magnetic Seeds to Locate Clipped Nodes After Neoadjuvant Chemotherapy for Breast Cancer Patients.
    Ann Surg Oncol. 2021 Jan 8. pii: 10.1245/s10434-020-09542.
    PubMed         Abstract available
    
    
21. JAMES TA, Fan B
    ASO Author Reflections: Using Tumor Genomics to Predict Axillary Response to Chemotherapy in Breast Cancer.
    Ann Surg Oncol. 2021 Jan 8. pii: 10.1245/s10434-020-09455.
    PubMed        
    
    

    
    Anticancer Res

22. SAGARA M, Miyamoto S, Itoh S, Soda Y, et al
    Development of New Oncolytic Virotherapy Targeting Breast Cancer Using Coxsackievirus B3.
    Anticancer Res. 2021;41:81-89.
    PubMed         Abstract available
    
    
23. OBA T, Maeno K, Ono M, Ito T, et al
    Prognostic Nutritional Index Is Superior to Neutrophil-to-lymphocyte Ratio as a Prognostic Marker in Metastatic Breast Cancer Patients Treated With Eribulin.
    Anticancer Res. 2021;41:445-452.
    PubMed         Abstract available
    
    
24. SCHMIDT M, KUmmel S, Ruf-Doerdelmann A, Distelrath A, et al
    Neo-adjuvant and/or Adjuvant Subcutaneous Trastuzumab (Herceptin((R))) in Patients With Early HER2-positive Breast Cancer: Real World Data from a German Observational Study - (NIS HerSCin).
    Anticancer Res. 2021;41:485-496.
    PubMed         Abstract available
    
    

    
    BMC Cancer

25. NAKATSUKASA K, Niikura N, Kashiwabara K, Amemiya T, et al
    Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC.
    BMC Cancer. 2021;21:34.
    PubMed         Abstract available
    
    
26. MOSLEMI M, Moradi Y, Dehghanbanadaki H, Afkhami H, et al
    The association between ATM variants and risk of breast cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:27.
    PubMed         Abstract available
    
    
27. FAHLBUSCH SS, Keil S, Epplen JT, Zanker KS, et al
    Comparison of hybrid clones derived from human breast epithelial cells and three different cancer cell lines regarding in vitro cancer stem/ initiating cell properties.
    BMC Cancer. 2020;20:446.
    PubMed         Abstract available
    
    

    
    Br J Cancer

28. BROAD RV, Jones SJ, Teske MC, Wastall LM, et al
    Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy.
    Br J Cancer. 2021 Jan 4. pii: 10.1038/s41416-020-01226.
    PubMed         Abstract available
    
    

    
    Breast Cancer

29. OHNUKI K, Tohno E, Tsunoda H, Uematsu T, et al
    Overall assessment system of combined mammography and ultrasound for breast cancer screening in Japan.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01203.
    PubMed         Abstract available
    
    
30. OEI SL, Thronicke A, Matthes H, Schad F, et al
    Assessment of integrative non-pharmacological interventions and quality of life in breast cancer patients using real-world data.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01193.
    PubMed         Abstract available
    
    
31. YAMAGUCHI K, Hara Y, Kitano I, Hamamoto T, et al
    Relationship between MRI findings and invasive breast cancer with podoplanin-positive cancer-associated fibroblasts.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01198.
    PubMed         Abstract available
    
    
32. MIYAKE T, Shimoda M, Tanei T, Kagara N, et al
    Sentinel lymph node biopsy after introducing Twirl(R) breast markers into suspicious lymph nodes in breast cancer patients.
    Breast Cancer. 2021 Jan 3. pii: 10.1007/s12282-020-01195.
    PubMed         Abstract available
    
    
33. FUJISAWA F, Kunimasa K, Kano-Fujiwara R, Sato Y, et al
    STK11 loss drives rapid progression in a breast cancer patient resulting in pulmonary tumor thrombotic microangiopathy.
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01200.
    PubMed         Abstract available
    
    
34. YOKOE T, Kurozumi S, Nozawa K, Ozaki Y, et al
    Clinical benefit of treatment after trastuzumab emtansine for HER2-positive metastatic breast cancer: a real-world multi-centre cohort study in Japan (WJOG12519B).
    Breast Cancer. 2021 Jan 2. pii: 10.1007/s12282-020-01192.
    PubMed         Abstract available
    
    
35. NEDELJKOVIC M, Tanic N, Prvanovic M, Milovanovic Z, et al
    Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
    Breast Cancer. 2021 Jan 8. pii: 10.1007/s12282-020-01210.
    PubMed         Abstract available
    
    
36. CAO W, Jiang Y, Ji X, Ma L, et al
    An immune-related risk gene signature predicts the prognosis of breast cancer.
    Breast Cancer. 2021 Jan 5. pii: 10.1007/s12282-020-01201.
    PubMed         Abstract available
    
    
37. YEN TWF, Garacci Z, Laud PW, Pezzin LE, et al
    Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer.
    Breast Cancer. 2021 Jan 4. pii: 10.1007/s12282-020-01206.
    PubMed         Abstract available
    
    

    
    Breast Cancer (Auckl)

38. ASAOKA M, Gandhi S, Ishikawa T, Takabe K, et al
    Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future.
    Breast Cancer (Auckl). 2020;14:1178223420980377.
    PubMed         Abstract available
    
    
39. SARMA M, Abdou Y, Dhakal A, Gandhi S, et al
    Significance of the Genomic Landscape of a De Novo Endocrine-Resistant Metastatic Hormone Receptor-Positive Breast Cancer.
    Breast Cancer (Auckl). 2020;14:1178223420976387.
    PubMed         Abstract available
    
    
40. SILVA-IGUA L, De La Pena J, Rubiano W, Ruiz-Sternberg AM, et al
    Premenopausal breast cancer is a health challenge: nutritional habits show potential to prevent this disease.
    Breast Cancer (Auckl). 2020;14:1178223420974665.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res

41. SOBOTTKA B, Moch H, Varga Z
    Differential PD-1/LAG-3 expression and immune phenotypes in metastatic sites of breast cancer.
    Breast Cancer Res. 2021;23:4.
    PubMed         Abstract available
    
    
42. HOWARTH KD, Mirza T, Cooke SL, Chin SF, et al
    NRG1 fusions in breast cancer.
    Breast Cancer Res. 2021;23:3.
    PubMed         Abstract available
    
    
43. LIAO YM, Wang YH, Hung JT, Lin YJ, et al
    High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Breast Cancer Res. 2021;23:5.
    PubMed         Abstract available
    
    
44. SANCHEZ K, Kim I, Chun B, Pucilowska J, et al
    Multiplex immunofluorescence to measure dynamic changes in tumor-infiltrating lymphocytes and PD-L1 in early-stage breast cancer.
    Breast Cancer Res. 2021;23:2.
    PubMed         Abstract available
    
    
45. PRIEDIGKEIT N, Ding K, Horne W, Kolls JK, et al
    Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences.
    Breast Cancer Res. 2021;23:1.
    PubMed         Abstract available
    
    

    
    Breast Cancer Res Treat

46. MORAVEK MB, Confino R, Lawson AK, Smith KN, et al
    Predictors and outcomes in breast cancer patients who did or did not pursue fertility preservation.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06031.
    PubMed         Abstract available
    
    
47. WILLIAMS AM, Khan CP, Heckler CE, Barton DL, et al
    Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06067.
    PubMed         Abstract available
    
    
48. KUMAR U, Ardasheva A, Mahmud Z, Coombes RC, et al
    FOXA1 is a determinant of drug resistance in breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06068.
    PubMed         Abstract available
    
    
49. SOARES ICS, Bello MA, Bergmann A, Thuler LCS, et al
    Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.
    Breast Cancer Res Treat. 2021 Jan 8. pii: 10.1007/s10549-020-06077.
    PubMed         Abstract available
    
    
50. WEI M, Wang X, Zimmerman DN, Burt LM, et al
    Endocrine therapy and radiotherapy use among older women with hormone receptor-positive, clinically node-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 9. pii: 10.1007/s10549-020-06071.
    PubMed         Abstract available
    
    
51. PASZAT L, Sutradhar R, Rakovitch E
    The impact of ductal carcinoma in situ on health services utilization.
    Breast Cancer Res Treat. 2020;182:159-168.
    PubMed         Abstract available
    
    
52. FRASSON AL, Lichtenfels M, de Souza AAB, Vollbrecht B, et al
    Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.
    Breast Cancer Res Treat. 2020;181:69-75.
    PubMed         Abstract available
    
    
53. LIU W, Li W, Li Z, Shi L, et al
    Ultrasound characteristics of sclerosing adenosis mimicking breast carcinoma.
    Breast Cancer Res Treat. 2020;181:127-134.
    PubMed         Abstract available
    
    
54. OLIVERI S, Ongaro G, Durosini I, Curigliano G, et al
    Breast implant-associated anaplastic large cell lymphoma: emotional impact and guidelines for psychological support.
    Breast Cancer Res Treat. 2020;181:221-224.
    PubMed         Abstract available
    
    
55. PURRINGTON KS, Gorski D, Simon MS, Hastert TA, et al
    Racial differences in estrogen receptor staining levels and implications for treatment and survival among estrogen receptor positive, HER2-negative invasive breast cancers.
    Breast Cancer Res Treat. 2020;181:145-154.
    PubMed         Abstract available
    
    
56. DI MICCO R, Classe JM, Reimer T
    Letter to the Editor regarding the publication titled "Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?"
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06064.
    PubMed        
    
    
57. VAN MECHELEN M, Van Herck A, Punie K, Nevelsteen I, et al
    Correction to: Behavior of metastatic breast cancer according to subtype.
    Breast Cancer Res Treat. 2021 Jan 7. pii: 10.1007/s10549-020-06006.
    PubMed        
    
    
58. KHOURY K, Lynce F, Barac A, Geng X, et al
    Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06053.
    PubMed         Abstract available
    
    
59. ZEIDMAN M, Schmidt H, Alberty-Oller JJ, Pisapati KV, et al
    Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06041.
    PubMed         Abstract available
    
    
60. SUTHERLAND A, Wagner JL, Korentager S, Butterworth J, et al
    Is bioimpedance spectroscopy a useful tool for objectively assessing lymphovenous bypass surgical outcomes in breast cancer-related lymphedema?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06059.
    PubMed         Abstract available
    
    
61. RAJAGOPAL T, Seshachalam A, Rathnam KK, Jothi A, et al
    Impact of xenobiotic-metabolizing gene polymorphisms on breast cancer risk in South Indian women.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06028.
    PubMed         Abstract available
    
    
62. KLEINSTERN G, Scott CG, Tamimi RM, Jensen MR, et al
    Association of mammographic density measures and breast cancer "intrinsic" molecular subtypes.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06049.
    PubMed         Abstract available
    
    
63. KIM JS, Kim K, Jung W, Shin KH, et al
    New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06043.
    PubMed         Abstract available
    
    
64. BOUWER NI, Steenbruggen TG, van Rosmalen J, Rier HN, et al
    Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06039.
    PubMed         Abstract available
    
    
65. GAUDET MM, Deubler E, Diver WR, Puvanesarajah S, et al
    Breast cancer risk factors by mode of detection among screened women in the Cancer Prevention Study-II.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06025.
    PubMed         Abstract available
    
    
66. MACKEY JR, Lai J, Chauhan U, Beauchamp E, et al
    N-myristoyltransferase proteins in breast cancer: prognostic relevance and validation as a new drug target.
    Breast Cancer Res Treat. 2021 Jan 4. pii: 10.1007/s10549-020-06037.
    PubMed         Abstract available
    
    
67. KONISHI T, Fujiogi M, Michihata N, Morita K, et al
    Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan.
    Breast Cancer Res Treat. 2021 Jan 5. pii: 10.1007/s10549-020-06069.
    PubMed         Abstract available
    
    
68. DO WL, Conneely K, Gabram-Mendola S, Krishnamurti U, et al
    Obesity-associated methylation in breast tumors: a possible link to disparate outcomes?
    Breast Cancer Res Treat. 2020;181:135-144.
    PubMed         Abstract available
    
    
69. MUKHTAR RA, Krings G, Chen YY, Mamounas ME, et al
    Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    Breast Cancer Res Treat. 2020;181:23-29.
    PubMed         Abstract available
    
    
70. KLAESTAD E, Sawicka JE, Engstrom MJ, Ytterhus B, et al
    ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
    Breast Cancer Res Treat. 2021 Jan 2. pii: 10.1007/s10549-020-06035.
    PubMed         Abstract available
    
    
71. LEONE JP, Leone BA, Zwenger AO, Vallejo CT, et al
    The prognostic significance of metastatic pattern in stage IV male breast cancer at initial diagnosis: a population-based study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06052.
    PubMed         Abstract available
    
    
72. SHLIAKHTUNOU YA
    CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients: continuous non-randomized prospective study and prospective randomized controlled study.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06036.
    PubMed         Abstract available
    
    
73. TZEKAKI EE, Geromichalos G, Lavrentiadou SN, Tsantarliotou MP, et al
    Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06054.
    PubMed         Abstract available
    
    
74. KANG YJ, Oh SJ, Choi H, Cho S, et al
    Clinical significance of HER2 status in T1bN0 breast cancer: a nationwide study from the Korean Breast Cancer Society.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06017.
    PubMed         Abstract available
    
    
75. LUANGWATTANANUN P, Junking M, Sujjitjoon J, Wutti-In Y, et al
    Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06032.
    PubMed         Abstract available
    
    
76. KENNARD K, Buckley ME, Sizer LM, Larson S, et al
    Metabolic Syndrome: does this influence breast cancer outcomes in the triple-negative population?
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06034.
    PubMed         Abstract available
    
    
77. JONES S, Hogan B, Patel K, Ooi S, et al
    Identification of factors that influence the decision to take chemoprevention in patients with a significant family history of breast cancer: results from a patient questionnaire survey.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06046.
    PubMed         Abstract available
    
    
78. POLLEY MC, Leon-Ferre RA, Leung S, Cheng A, et al
    A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06030.
    PubMed         Abstract available
    
    
79. STENEHJEM DD, Telford C, Unni SK, Bauer H, et al
    BRCA testing and outcomes in women with breast cancer.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06038.
    PubMed         Abstract available
    
    
80. GUVAKOVA MA, Prabakaran I, Wu Z, Hoffman DI, et al
    CDH2/N-cadherin and early diagnosis of invasion in patients with ductal carcinoma in situ.
    Breast Cancer Res Treat. 2020;183:333-346.
    PubMed         Abstract available
    
    
81. BROWNE JL, Korsun N, Casas L, Rodriguez I, et al
    "Are changes in breast density during the menstrual cycle relevant? To what?"
    Breast Cancer Res Treat. 2020;183:451-458.
    PubMed         Abstract available
    
    
82. LI Z, Wang Y, Liu C, Wang Z, et al
    Association between VEGF single nucleotide polymorphism and breast cancer in the Northern China Han population.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06024.
    PubMed         Abstract available
    
    
83. DOFARA SG, Chang SL, Diorio C
    Association between the polymorphisms in MMP-2 and MMP-9 with adiposity and mammographic features.
    Breast Cancer Res Treat. 2020;182:169-179.
    PubMed         Abstract available
    
    
84. RAMZI S, Najeeb E, Coulthard J, Jenkins S, et al
    Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?
    Breast Cancer Res Treat. 2020;182:47-54.
    PubMed         Abstract available
    
    
85. VAN STEENHOVEN JEC, den Dekker BM, Kuijer A, van Diest PJ, et al
    Patients' perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict.
    Breast Cancer Res Treat. 2020;182:107-115.
    PubMed         Abstract available
    
    
86. GOETZ MP, Okera M, Wildiers H, Campone M, et al
    Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
    Breast Cancer Res Treat. 2021 Jan 3. pii: 10.1007/s10549-020-06029.
    PubMed         Abstract available
    
    
87. HENDRIKS MP, Verbeek XAAM, van Manen JG, van der Heijden SE, et al
    Clinical decision trees support systematic evaluation of multidisciplinary team recommendations.
    Breast Cancer Res Treat. 2020;183:355-363.
    PubMed         Abstract available
    
    
88. LI K, Liao N, Chen B, Zhang G, et al
    Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy.
    Breast Cancer Res Treat. 2020;183:321-332.
    PubMed         Abstract available
    
    
89. JUNG JJ, Kang E, Kim EK, Kim SM, et al
    External validation and modification of nomogram for predicting positive resection margins before breast conserving surgery.
    Breast Cancer Res Treat. 2020;183:373-380.
    PubMed         Abstract available
    
    
90. WONG EC, Kaplan CP, Barulich M, Melisko M, et al
    Assessing preferences for receiving supportive care resources among patients seen at a Breast Care Center.
    Breast Cancer Res Treat. 2020;183:381-389.
    PubMed         Abstract available
    
    
91. KAIDAR-PERSON O, Poortmans P, Offersen BV, Siesling S, et al
    Spatial location of local recurrences after mastectomy: a systematic review.
    Breast Cancer Res Treat. 2020;183:263-273.
    PubMed         Abstract available
    
    

    
    Breast J

92. SYED A, Premi V, Varghese R, Arora M, et al
    Role of breast imaging with histopathological correlation in evaluating the response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Breast J. 2020;26:2272-2275.
    PubMed        
    
    
93. SCHMIDT H, Zhaveri S, Valente C, Pisapati K, et al
    Response in breast vs axilla after neoadjuvant treatment and implications for nonoperative management of invasive breast cancer.
    Breast J. 2021 Jan 3. doi: 10.1111/tbj.14125.
    PubMed         Abstract available
    
    

    
    Cancer

94. PRINTZ C
    Drug shows significant early promise in early, high-risk, HR-positive, HER2-negative breast cancer: Interim data indicate that adding abemaciclib to hormonal therapy reduces recurrence risk.
    Cancer. 2021;127:169-170.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

95. MEHRAJ U, Dar AH, Wani NA, Mir MA, et al
    Tumor microenvironment promotes breast cancer chemoresistance.
    Cancer Chemother Pharmacol. 2021 Jan 9. pii: 10.1007/s00280-020-04222.
    PubMed         Abstract available
    
    

    
    Cancer Res

96. TROTTER TN, Shuptrine CW, Tsao LC, Marek RD, et al
    IL-26, a non-canonical mediator of DNA inflammatory stimulation, promotes TNBC engraftment and progression in association with neutrophils.
    Cancer Res. 2020 May 4. pii: 0008-5472.CAN-18-3825.
    PubMed         Abstract available
    
    
97. VERRET B, Sourisseau T, Stefanovska B, Mosele F, et al
    The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.
    Cancer Res. 2020;80:3062-3069.
    PubMed         Abstract available
    
    
98. MILLER KD, Pniewski K, Perry CE, Papp SB, et al
    Targeting ACSS2 with a transition state mimetic inhibits triple-negative breast cancer growth.
    Cancer Res. 2021 Jan 7. pii: 0008-5472.CAN-20-1847.
    PubMed         Abstract available
    
    
99. LIU Z, Sun L, Cai Y, Shen S, et al
    Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1.
    Cancer Res. 2021 Jan 5. pii: 0008-5472.CAN-20-2876.
    PubMed         Abstract available
    
    

    
    Clin Breast Cancer

100. AL-SALEH K, Aldiab A, Salah T, Arafah M, et al
     Prognostic Significance of HER2 Expression Changes Following Neoadjuvant Chemotherapy in Saudi Patients With Locally Advanced Breast Cancer.
     Clin Breast Cancer. 2020 Dec 3. pii: S1526-8209(20)30324.
     PubMed         Abstract available
     
     
101. FORTUNATO L, d'Amati G, Taffurelli M, Tinterri C, et al
     Severe Impact of Covid-19 Pandemic on Breast Cancer Care in Italy: A Senonetwork National Survey.
     Clin Breast Cancer. 2020 Nov 2. pii: S1526-8209(20)30271.
     PubMed        
     
     

     
     Clin Cancer Res

102. ESSERMAN LJ
     Personalization of Treatment is the Way Forward in Care and Trials.
     Clin Cancer Res. 2020;26:2771-2773.
     PubMed         Abstract available
     
     
103. MA L, Gonzalez-Junca A, Zheng Y, Ouyang H, et al
     Inflammation mediates the development of aggressive breast cancer following radiotherapy.
     Clin Cancer Res. 2021 Jan 5. pii: 1078-0432.CCR-20-3215.
     PubMed         Abstract available
     
     

     
     Clin Exp Metastasis

104. MAITI E
     Modeling breast cancer survival and metastasis rates from moderate-sized clinical data.
     Clin Exp Metastasis. 2021 Jan 3. pii: 10.1007/s10585-020-10066.
     PubMed         Abstract available
     
     

     
     Eur J Cancer

105. JEONG JH, Kim JE, Ahn JH, Jung KH, et al
     Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
     Eur J Cancer. 2020;144:341-350.
     PubMed         Abstract available
     
     
106. ROBERTSON JFR, Paridaens RJ, Lichfield J, Bradbury I, et al
     Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
     Eur J Cancer. 2021;145:19-28.
     PubMed         Abstract available
     
     
107. DUBSKY P, Tausch C
     Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by Pfob et al.
     Eur J Cancer. 2021;143:178-179.
     PubMed        
     
     
108. R FERREIRA A, Ferreira S, Lambertini M, Maurer C, et al
     Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial.
     Eur J Cancer. 2020;144:351-359.
     PubMed         Abstract available
     
     

     
     Eur Radiol

109. ROMAN M, Louro J, Posso M, Alcantara R, et al
     Breast density, benign breast disease, and risk of breast cancer over time.
     Eur Radiol. 2021 Jan 6. pii: 10.1007/s00330-020-07490.
     PubMed         Abstract available
     
     

     
     Histopathology

110. TIEN TZ, Lee JNLW, Lim JCT, Chen XY, et al
     Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence (mIHC/IF).
     Histopathology. 2021 Jan 5. doi: 10.1111/his.14328.
     PubMed         Abstract available
     
     

     
     Int J Cancer

111. MANICHAIKUL A, Peres LC, Wang XQ, Barnard ME, et al
     Identification of novel epithelial ovarian cancer loci in Women of African Ancestry.
     Int J Cancer. 2019 Aug 30. doi: 10.1002/ijc.32653.
     PubMed         Abstract available
     
     

     
     Int J Radiat Oncol Biol Phys

112. CHUNG SY, Oh J, Chang JS, Shin J, et al
     Risk of Cardiac Disease in Breast Cancer Patients: Impact of Patient-Specific Factors and Individual Heart Dose from Three-Dimensional Radiotherapy Planning.
     Int J Radiat Oncol Biol Phys. 2021 Jan 6. pii: S0360-3016(21)00003.
     PubMed         Abstract available
     
     
113. CHOI SH, Chang JS, Son NH, Hong CS, et al
     Risk of Hypothyroidism in Women after Radiotherapy for Breast Cancer.
     Int J Radiat Oncol Biol Phys. 2021 Jan 4. pii: S0360-3016(20)34743.
     PubMed         Abstract available
     
     

     
     J Clin Invest

114. DERSH D, Yewdell JW
     Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation.
     J Clin Invest. 2021;131.
     PubMed         Abstract available
     
     

     
     J Clin Oncol

115. MCNEIL CM
     Coronavirus Farewell.
     J Clin Oncol. 2020;38:4346-4348.
     PubMed        
     
     

     
     NPJ Breast Cancer

116. WANG J, Ma G, Ge H, Han X, et al
     Circulating tRNA-derived small RNAs (tsRNAs) signature for the diagnosis and prognosis of breast cancer.
     NPJ Breast Cancer. 2021;7:4.
     PubMed         Abstract available
     
     
117. WEHRSE E, Sawall S, Klein L, Glemser P, et al
     Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients.
     NPJ Breast Cancer. 2021;7:3.
     PubMed         Abstract available
     
     
118. LOKKEGAARD S, Elias D, Alves CL, Bennetzen MV, et al
     MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
     NPJ Breast Cancer. 2021;7:2.
     PubMed         Abstract available
     
     
119. GIRO-PERAFITA A, Luo L, Khodadadi-Jamayran A, Thompson M, et al
     LncRNA RP11-19E11 is an E2F1 target required for proliferation and survival of basal breast cancer.
     NPJ Breast Cancer. 2020;6:1.
     PubMed         Abstract available
     
     
120. SCHETTINI F, Chic N, Braso-Maristany F, Pare L, et al
     Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer.
     NPJ Breast Cancer. 2021;7:1.
     PubMed         Abstract available
     
     

     
     Oncogene

121. PANTANO F, Croset M, Driouch K, Bednarz-Knoll N, et al
     Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions.
     Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01603.
     PubMed         Abstract available
     
     
122. YOUSEFI H, Vatanmakanian M, Mahdiannasser M, Mashouri L, et al
     Understanding the role of integrins in breast cancer invasion, metastasis, angiogenesis, and drug resistance.
     Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01588.
     PubMed         Abstract available
     
     
123. VARESLIJA D, Ward E, Purcell SP, Cosgrove NS, et al
     Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.
     Oncogene. 2021 Jan 8. pii: 10.1038/s41388-020-01606.
     PubMed         Abstract available
     
     

     
     Oncol Rep

124. ZENG A, Liang X, Zhu S, Liu C, et al
     Chlorogenic acid induces apoptosis, inhibits metastasis and improves antitumor immunity in breast cancer via the NFkappaB signaling pathway.
     Oncol Rep. 2020 Dec 9. doi: 10.3892/or.2020.7891.
     PubMed         Abstract available
     
     
125. GANTOV M, Pagnotta P, Lotufo C, Rindone GM, et al
     Beige adipocytes contribute to breast cancer progression.
     Oncol Rep. 2020 Oct 27. doi: 10.3892/or.2020.7826.
     PubMed         Abstract available
     
     
126. ZHANG T, Zhang W, Hao M
     Phenethyl isothiocyanate reduces breast cancer stem cell-like properties by epigenetic reactivation of CDH1.
     Oncol Rep. 2020 Nov 19. doi: 10.3892/or.2020.7860.
     PubMed         Abstract available
     
     
127. LI CJ, Lin LT, Hou MF, Chu PY, et al
     PDL1/PD1 blockade in breast cancer: The immunotherapy era (Review).
     Oncol Rep. 2020 Nov 3. doi: 10.3892/or.2020.7831.
     PubMed         Abstract available
     
     
128. KASHKOULINEJAD-KOUHI T, Safarian S, Arnaiz B, Saa L, et al
     Enhancement of cisplatin sensitivity in human breast cancer MCF-7 cell line through BiP and 14-3-3zeta co-knockdown.
     Oncol Rep. 2020 Dec 14. doi: 10.3892/or.2020.7898.
     PubMed         Abstract available
     
     

     
     PLoS Med

129. CARREIRA H, Williams R, Funston G, Stanway S, et al
     Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom.
     PLoS Med. 2021;18:e1003504.
     PubMed         Abstract available
     
     

     
     PLoS One

130. MOUSTAFA D, Elwahed MRA, Elsaid HH, Parvin JD, et al
     Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
     PLoS One. 2021;16:e0235025.
     PubMed         Abstract available
     
     
131. WINNARD PT JR, Vesuna F, Muthukumar S, Raman V, et al
     Divergent organ-specific isogenic metastatic cell lines identified using multi-omics exhibit differential drug sensitivity.
     PLoS One. 2020;15:e0242384.
     PubMed         Abstract available
     
     

     
     Proc Natl Acad Sci U S A

132. WEAVER VM, Bissell MJ
     Zena Werb (1945-2020): Mourning the loss of a tissue microenvironment icon.
     Proc Natl Acad Sci U S A. 2020;117:27759-27760.
     PubMed        
     
     

     
     Radiother Oncol

133. WIERCINSKA J, Winiecki J, Wronczewska A, Lebioda A, et al
     The use of hyaluronic acid hydrogel as a tumour bed marker in breast-conserving therapy.
     Radiother Oncol. 2020;152:8-13.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: